Science and Technology

Author Archive | xchem-editor

March 13, 2018

X-Chem Announces Licensing of Two Discovery Programs to AbbVie

Small molecule drug discovery specialist XChem, Inc. today announced that AbbVie has exercised options to license two discovery programs. Under the terms of the parties’ 2016 multi-target research collaboration, AbbVie had an option to an exclusive license to the programs, each of which comprises multiple novel, cell-active modulators of two historically challenging targets in oncology […]

Continue Reading
December 13, 2017

X-Chem and Abilita Bio Announce a Joint Research Collaboration

(XChem), and Abilita Bio, Inc. (Abilita), both privately held biotechnology companies, announce today a joint research collaboration that will leverage the synergy between each company’s platform technology to enable the discovery of novel modulators of high-value G-protein coupled receptors (GPCR) and ion channel targets.

Continue Reading
November 28, 2017

X-Chem and Gilead Announce Drug Discovery Collaboration

WALTHAM, Mass. – November 28, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Gilead Sciences, Inc. (Gilead). Under the terms of the agreement, XChem will screen its proprietary DEXTM libraries, which contain […]

Continue Reading
October 31, 2017

Consortium of X-Chem, Harvard T.H. Chan School of Public Health and Other Leading Academic Institutions Wins Research Award from the Department of Defense

X-Chem, Inc., a privately held biotechnology company with a proprietary and innovative platform to generate small molecule therapeutics, today announced the award of a DOD CDMRP research grant entitled “Chemigenomic Drug Discovery for Tuberculosis.” The grant was awarded to a research consortium led by Eric Rubin, M.D., Ph.D., Irene Heinz professor of Immunology and Infectious […]

Continue Reading
October 27, 2017

Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action

October 18, 2017|ACS Chemical Biology|Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action ATAD2 (ANCCA) is an epigenetic regulator and transcriptional cofactor, whose overexpression has been linked to the progress of various cancer types. Here, we report a DNA-encoded library screen leading to the discovery of BAY-850, a potent and isoform […]

Continue Reading